DUBLIN–(BUSINESS WIRE)–The “Whole Genome and Exome Sequencing Market: By Application, Organism and Product with Executive and Consultant Guides” report has been added to ResearchAndMarkets.com’s offering. Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What’s holding the industry back? Where are over 800 locations that have high throughput devices? New consumers, new technologies, new spe

JACKSONVILLE, Fla.–(BUSINESS WIRE)–MMI will present in the private track at the 43rd J.P. Morgan Healthcare Conference, marking its 3rd year showcasing open surgery innovations.

HAWTHORNE, Calif.–(BUSINESS WIRE)–OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that its Security division received an order valued at approximately $23 million to assist in the deployment and integration of long-range radio frequency (RF) critical communication systems. As part of the award, the Company is expected to provide critical hardware as well as technical services designed to enhance the long-term availability of US government strategic RF communi

SAN FRANCISCO & SEATTLE–(BUSINESS WIRE)– #HealthWayFinding–Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent will acquire Accolade for $7.03 per share in cash, which represents a total equity value of approximately $621M. This strategic combination, which has been unanimously approved by the Boards of Directors of both companies, w

CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict patient response to treatment.

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People’s Republic of China, today announced an exclusive licensing agreement for the

BOSTON–(BUSINESS WIRE)– #CRO–Ora announces appointment of Cindy Markham as Chief Commercial Officer

ONTARIO, Calif.–(BUSINESS WIRE)–The Prime Healthcare Foundation and the Central Maine Healthcare (CMH) Board of Directors announced they have reached an agreement for Prime Healthcare Foundation to become the sole corporate member and parent company of Central Maine Healthcare. The agreement includes the following facilities: Central Maine Medical Center, Bridgton Hospital, Rumford Hospital, Rumford Community Home, Bolster Heights, Maine College of Health Professions, CMH Cancer Care Center,

CAMBRIDGE, Mass. & SINGAPORE–(BUSINESS WIRE)–Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, today announced the appointment of Richard Batrla, M.D., Ph.D., MBA as chief medical officer. “There couldn’t be a better time to welcome Richard to the team as we embark on a new year and anticipate several exciting milestones ahead,” said John McDonough, executive chairman and CE

STAMFORD, Conn.–(BUSINESS WIRE)–GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through understanding gene-disease relationships, contributing to more than 85 peer-reviewed publications in 2024. These contributions, added to GeneDx’s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance, and ulti